The principles underlying programmed cell death‐1 (PD‐1) or programmed death ligand‐1 (PD‐L1) inhibition as a cancer immunotherapy are well established,1 and single agents targeting this pathway have demonstrated encouraging activity across multiple solid tumor types.1, 2. The gene discussed is CD274; the disease is cancer.